ACC Action Center
Welcome to the ACC Action Center, bringing you the latest updates from the American College of Cardiology’s Annual Scientific Session & Expo, hosted in partnership with the World Congress of Cardiology. This collection will highlight emerging clinical data and explore the latest practice-changing advances in the field of cardiology.
31-45 of 67
Promising results for self-expanding TAVR device in trial with mostly women
ACC Action CenterPromising results for self-expanding TAVR device in trial with mostly women
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC Action CenterAngiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Preventive PCI versus optimal medical therapy only for vulnerable plaques
ACC Action CenterPreventive PCI versus optimal medical therapy only for vulnerable plaques
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC Action CenterPromising results for APOC3 ASO in familial chylomicronemia syndrome
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC Action CenterIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Self-assessment on statin eligibility without prescription using a web app
ACC Action CenterSelf-assessment on statin eligibility without prescription using a web app
- advertisement
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
ACC Action CenterMore than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
Stopping aspirin after 1 month DAPT in ACS patients after stenting
ACC Action CenterStopping aspirin after 1 month DAPT in ACS patients after stenting
Head-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
ACC Action CenterHead-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
ACC Action CenterAPOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC Action CenterNo improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC Action CenterEarly aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
- advertisement
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
ACC Action CenterNo effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Closing Gaps in Care for Patients with T2D & CV Disease
Diabetes DiscourseClosing Gaps in Care for Patients with T2D & CV Disease
